Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 28, 2023 07:00 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics Successfully Treats First Patient in Cohort 8 of ReSPECT-GBM Phase 1/2a Trial

Company also enrolling ReSPECT-GBM Phase 2 trial Presentation of data from Phase 1/2a and Phase 2 trials planned in 2023 AUSTIN, Texas, March 28, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc....
March 22, 2023 07:00 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics Initiates Cohort 3 in Phase 1/Part A of the ReSPECT-LM Trial for Leptomeningeal Metastases

AUSTIN, Texas, March 22, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
February 23, 2023 16:05 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

Initiated ReSPECT-GBM Phase 2 and ReSPECT- LM Phase 1 trials for CNS cancers Awarded $17.6 million Cancer Prevention & Research Institute of Texas (CPRIT) grant to support clinical development of...
February 14, 2023 07:00 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023

AUSTIN, Texas, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for...
February 01, 2023 07:00 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics Completes Enrollment in Second ReSPECT-LM Phase 1 Trial Cohort of Rhenium (¹⁸⁶Re) Obisbemeda for the Treatment of Leptomeningeal Metastases

AUSTIN, Texas, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
January 18, 2023 07:00 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics Announces First Patient Dosed in ReSPECT-GBM Phase 2b Trial of Rhenium (186Re) Obisbemeda for Treatment of Recurrent Glioblastoma

AUSTIN, Texas, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
November 19, 2022 08:24 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics Provides Updates on ReSPECT™ Clinical Trials at the 27th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology

ReSPECT-GBM clinical trial of rhenium (186Re) obisbemeda in recurrent glioblastoma continues to demonstrate safety and overall survival correlates with radiation dose to tumor ReSPECT-GBM Phase 2...
November 02, 2022 07:00 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics to Provide Update on ReSPECT™ Clinical Trials at the 27th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology

Recurrent glioblastoma and leptomeningeal metastases data have been selected for oral presentations Pediatric brain cancer plans will be shared via poster session AUSTIN, Texas, Nov. 02, 2022 ...
October 26, 2022 07:00 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics Announces Selection of “Rhenium (186Re) Obisbemeda” as International Non-Proprietary Name for 186RNL

AUSTIN, Texas, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for...
October 20, 2022 16:05 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

Awarded $17.6 million Product Development Research grant by the Cancer Prevention & Research Institute of Texas (CPRIT) to fund 186RNL development for leptomeningeal metastases (LM) ...